keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunoglobulin

keyword
https://www.readbyqxmd.com/read/28063043/subcutaneous-and-sublingual-immunotherapy-in-a-mouse-model-of-allergic-asthma
#1
Laura Hesse, Martijn C Nawijn
Allergic asthma, caused by inhaled allergens such as house dust mite or grass pollen, is characterized by reversible airway obstruction, associated with an eosinophilic inflammation of the airways, as well as airway hyper responsiveness and remodeling. The inhaled allergens trigger a type-2 inflammatory response with involvement of innate lymphoid cells (ILC2) and Th2 cells, resulting in high production of immunoglobulin E (IgE) antibodies. Consequently, renewed allergen exposure results in a classic allergic response with a distinct early and late phase, both resulting in bronchoconstriction and shortness of breath...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28041678/update-on-the-use-of-immunoglobulin-in-human-disease-a%C3%A2-review-of-evidence
#2
Elena E Perez, Jordan S Orange, Francisco Bonilla, Javier Chinen, Ivan K Chinn, Morna Dorsey, Yehia El-Gamal, Terry O Harville, Elham Hossny, Bruce Mazer, Robert Nelson, Elizabeth Secord, Stanley C Jordan, E Richard Stiehm, Ashley A Vo, Mark Ballow
Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted...
December 24, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28028342/kimura-s-disease-a-diagnostic-challenge-experienced-with-cytology-of-postauricular-swelling-with-histopathological-relevance
#3
Mingma Sherpa, Rachna Lamichaney, Asitava Deb Roy
Kimura's disease is a rare, chronic inflammatory disorder of unknown cause. It is endemic in Asia, affecting more number of males than females, with a ratio of 3:1. The typical clinical manifestations include a triad of painless unilateral cervical lymphadenopathy or subcutaneous masses predominantly in the head and neck region, blood and tissue eosinophilia, and an elevated serum immunoglobulin E (IgE) levels. Variable conditions both benign and malignant may mimic Kimura's disease both clinically and on fine needle aspirates...
October 2016: Journal of Cytology
https://www.readbyqxmd.com/read/28000311/subcutaneous-immunoglobulin-as-first-line-therapy-in-treatment-naive-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-randomized-controlled-trial-study
#4
L H Markvardsen, S H Sindrup, I Christiansen, N K Olsen, J Jakobsen, H Andersen
BACKGROUND AND PURPOSE: Subcutaneous immunoglobulin (SCIG) is effective as maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). We investigated whether multiple subcutaneous infusions are as effective as conventional therapy with intravenous loading doses in treatment-naive patients with CIDP. METHODS: Twenty patients fulfilling the clinical and electrophysiological criteria for CIDP were included and treated with either SCIG (0.4 g/kg/week) for 5 weeks or intravenous immunoglobulin (IVIG) (0...
February 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/27996286/safety-and-efficacy-of-ant-rush-immunotherapy-in-children
#5
Wiparat Manuyakorn, Suwat Benjaponpitak, Wasu Kamchaisatian, Cherapat Sasisakulporn, Wanlapa Jotikasthira
BACKGROUND: The Rush Immunotherapy (RIT) protocol is a valid alternative in order to reach the maintenance phase early. However, there are scarce studies in the literature that have evaluated the safety and the efficacy of an ant RIT process in children. OBJECTIVE: To evaluate the safety and the efficacy of an ant RIT protocol and to identify the risk factors for systemic reactions (SRs) during an RIT procedure in children. METHOD: A retrospective review was conducted for those children who were receiving an ant RIT procedure...
December 12, 2016: Asian Pacific Journal of Allergy and Immunology
https://www.readbyqxmd.com/read/27989076/the-immune-responses-and-calcification-of-bioprostheses-in-the-%C3%AE-1-3-galactosyltransferase-knockout-mouse
#6
Woo Sung Jeong, Yong Jin Kim, Hong-Gook Lim, Saeromi Jung, Jeong Ryul Lee
BACKGROUND: The study aim was to evaluate the immune reaction, difference of degenerative calcification, and anti-calcification effect of decellularization with or without α-galactosidase in bovine pericardium and porcine heart valves, using an α1,3-galactosyltransferase (α-Gal) knockout (KO) mouse model. METHODS: In order to elucidate the anti-calcification effect of decellularization with or without α-galactosidase, bovine pericardium and porcine heart valve tissues were assigned to four groups according to the tissue preparation method: (i) glutaraldehyde (GA) fixation only; (ii) decellularization + GA fixation (Decell); (iii) α-galactosidase + GA fixation (α-galactosidase); and (iv) decellularization +α-galactosidase + GA fixation (Decell + α-galactosidase)...
March 2016: Journal of Heart Valve Disease
https://www.readbyqxmd.com/read/27931296/intravenous-and-subcutaneous-immunoglobulin-g-replacement-therapy
#7
Francisco A Bonilla
Human polyclonal immunoglobulin G (IgG) for therapeutic use has been available for decades. This drug was developed for treatment of antibody deficiency (replacement therapy), although its use has expanded into many anti-inflammatory and immunomodulatory applications in recent years. This review focuses on IgG prescribing for replacement therapy. IgG for replacement is most often administered via the intravenous IgG (IVIG) or subcutaneous IgG (SCIG) routes. IVIG is usually administered every 34 weeks, and SCIG is usually administered weekly, although variations may be considered in all cases...
November 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/27919413/new-choices-for-treatment-with-subcutaneous-immunoglobulins
#8
Daniel E Pleguezuelo, Silvia Sánchez-Ramón
No abstract text is available yet for this article.
January 20, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/27918219/a-new-treatment-regimen-with-high-dose-and-fractioned-immunoglobulin-in-a-special-subgroup-of-severe-and-dependent-cidp-patients
#9
Rabab Debs, Pauline Reach, Corina Cret, Sophie Demeret, Samir Saheb, Thierry Maisonobe, Karine Viala
BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is treated with intravenous immunoglobulins (IVIg), corticosteroids or plasma exchange (PE). IVIg dosage is not universal and markers for treatment management are needed. METHODS: We report the response to high-dose and fractioned IVIg in a subgroup of definite CIDP patients, resistant to corticosteroids and PE, responders to IVIg but with an efficacy window <15 d. RESULTS: Four patients were included with similar predominantly clinical motor form and conduction abnormalities...
December 20, 2016: International Journal of Neuroscience
https://www.readbyqxmd.com/read/27900974/disseminated-mycobacteria-chelonae-infection-in-a-kidney-pancreas-transplant-recipient-a-case-report-and-review-of-the-literature
#10
Shafi Malik, Ananda Ghosh, Shahid Husain
A 40-year-old male with a long-standing history of type 1 diabetes with end-stage renal failure underwent combined kidney-pancreas (KP) transplant from a standard criteria donor. Post-operative course was uncomplicated with good primary function of both transplant grafts. Induction was with thymoglobulin and maintenance immunosuppression was with tacrolimus, mycophenolate mofetil and prednisolone. Nine weeks post-transplant, the patient developed dysfunction of both grafts. Panel reactive antibody testing revealed that the patient had developed a de novo donor-specific antibody and considering an antibody-mediated rejection the patient was treated with intravenous pulse methyl prednisone 500 mg ×3 doses, IV immunoglobulin 2 mg/kg in two divided doses, and ATG 7 mg/kg (total dose of 700 mg)...
November 2016: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/27893674/relapsing-remitting-lesions-in-a-woman-with-progressive-hemifacial-atrophy-and-chronic-hepatitis-b-virus-infection-a-case-report
#11
Ying Zhang, Mingqin Zhu, Xiaozhen Li, Jing Miao, Chenchen Duan, Li Cui, Xuefan Yu
INTRODUCTION: Progressive hemifacial atrophy (PHA) is a rare disorder characterized by unilateral facial atrophy affecting the skin, subcutaneous tissue, and fat, muscle, and osteocartilagenous structures creating a sunken hemiface appearance.Etiopathogenesis of PHA is poorly understood; no definitive treatment is currently available. CLINICAL FINDINGS: We report a 41-year-old woman with PHA who showed an uncharacteristic "relapsing-remitting" evolution of brain lesions and was seropositive for hepatitis B virus (HBV)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27884454/-management-of-adverse-effects-related-to-human-immunoglobulin-therapy-recommendations-for-clinical-practice
#12
I Marie, P Chérin, M Michallet, E Pelus, J Dantal, J-C Crave, J-C Delain, J-F Viallard
Both intravenous and subcutaneous immunoglobulins are therapeutic modalities approved in various conditions, including primary and secondary immune deficiencies and autoimmune disorders. To date, immunoglobulins have more often been considered as a safe medication, with minor adverse effects such as hypertension, fever and chills, nausea, myalgia or headache. However, with the wider use of immunoglobulins in the treatment of autoimmune diseases, severe side effects have also been reported to occur in immunoglobulin-treated patients, especially anaphylaxis, aseptic meningitis, acute renal impairment, thrombotic events as well as haematological manifestations...
November 21, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27876304/effective-use-of-20-subcutaneous-immunoglobulin-therapy-in-a-man-with-preexisting-thrombi
#13
Carla Duff, Mandel R Sher, Jennifer W Leiding
No abstract text is available yet for this article.
January 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27861229/what-s-in-the-literature
#14
Nicholas J Silvestri, Gil I Wolfe, David Lacomis
In this edition, we focus on neuromuscular junction disorders and myopathy. The newly published international consensus guidelines for the management of myasthenia gravis are reviewed. In addition, various emerging treatment options for myasthenia, including the use of methotrexate, rituximab, subcutaneous immunoglobulin, and thymectomy, are discussed. Recent studies examining the clinical and genetic features of several forms of congenital myasthenia gravis are also highlighted. The clinical features and treatment of late-onset Pompe disease are reviewed, as are studies in facioscapulohumeral dystrophy, idiopathic inflammatory myopathies, and calpainopathy...
December 2016: Journal of Clinical Neuromuscular Disease
https://www.readbyqxmd.com/read/27860553/developing-an-inactivated-rotavirus-vaccine-and-evaluating-the-immunogenicity-against-a-commercially-available-attenuated-rotavirus-vaccine-using-a-mice-animal-model
#15
Ayaa S M Hashim, Khaled M A Aboshanab, Aly F M El-Sayed
There is a high demand for public immunization against Rotavirus (RV), especially in Africa. In Africa, the attenuated RV vaccination is contraindicated in patients with immune diseases and nutrition deficiency. Therefore, the inactivated RV vaccine (IRVV) could be an alternative. In this study, we aimed to develop a pentavalent-IRVV using the most circulating RV strains in Egypt and evaluate it against the commercially available Rotarix(®) vaccine. Trial-IRVV was developed with 5% sucrose, 2% polysorbate-80, and adsorbed on Alum to potentiate the vaccine immune response...
December 2016: Viral Immunology
https://www.readbyqxmd.com/read/27849353/evaluating-dose-ratio-of-subcutaneous-to-intravenous-immunoglobulin-therapy-among-patients-with-primary-immunodeficiency-disease-switching-to-20-subcutaneous-immunoglobulin-therapy
#16
Girishanthy Krishnarajah, Jee-Yeon K Lehmann, Brian Ellman, Rachel H Bhak, Maral DerSarkissian, Deane Leader, Ann L Bullinger, Mei Sheng Duh
BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary immunodeficiency disease (PI) from intravenous (IVIG) therapy to most subcutaneous therapy ([SCIG], except the 10% SCIG human hyaluronidase and immune globulin). However, a dose ratio of 1:1 was studied and approved for the European Union (EU). The dose-adjustment ratio used by prescribers in real-world US clinical practice is unknown...
October 2016: American Journal of Managed Care
https://www.readbyqxmd.com/read/27836057/the-nuts-and-bolts-of-immunoglobulin-treatment-for-antibody-deficiency
#17
Richard L Wasserman
Immunoglobulin therapy is a key element in the management of most patients with primary immunodeficiency disease. Allergist/immunologists should be familiar with the appropriate evaluation of candidates for immunoglobulin, the characteristics of immunoglobulin products, and how to use them to provide the best care to their patients. Available immunoglobulin products appear to be equally efficacious, but they are not interchangeable. Minimizing the risk of serious adverse events and controlling minor side effects is important to ideal patient care...
November 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27828933/practical-considerations-for-self-administration-of-subcutaneous-immunoglobulin-g-utilizing-recombinant-human-hyaluronidase-an-advanced-method-of-subcutaneous-administration-a-nurse-s-perspective
#18
Linda K Miars, Michelle Tran, Kimberly Duff
An approved subcutaneous infusion of immunoglobulin G using recombinant human hyaluronidase (IGHy) allows adult patients with primary immunodeficiency disease to self-administer every 3 to 4 weeks using 1 to 2 subcutaneous infusion site(s). This article reviews the practical considerations for nurses to simplify patient education and training. Key considerations include pump choice and parameters, ancillary supplies, and technique. Patient education includes infusion log upkeep and management of potential reactions...
November 2016: Journal of Infusion Nursing: the Official Publication of the Infusion Nurses Society
https://www.readbyqxmd.com/read/27822850/population-pharmacokinetics-pk-and-pharmacodynamics-pd-analysis-of-ly3015014-a-monoclonal-antibody-to-protein-convertase-subtilisin-kexin-type-9-pcsk9-in-healthy-subjects-and-hypercholesterolemia-patients
#19
Tong Shen, Douglas E James, Kathryn A Krueger
PURPOSE: LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9 and reduce low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia that is poorly controlled by maximally tolerated statin therapy. The objective of this pharmacokinetic/pharmacodynamics (PK/PD) analysis was to characterize the PK and PD properties of LY3015014 and assess the effect of covariates on the LY3015014 PK-PD profiles. METHODS: Single and multiple dose data from three phase1 studies in healthy subjects (n = 133), as well as a phase 2 study in hypercholesterolemia patients (n = 527) were combined into a single dataset for analysis...
January 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/27807853/aseptic-meningitis-following-therapy-with-immune-globulins-a-combination-of-product-features-and-patient-characteristics
#20
Roger Berg, Elisabeth Fuellenhals
BACKGROUND: Aseptic meningitis (AM) represents a recognized side effect of immune globulin (IG) therapy and may warrant additional diagnostic procedures and therapy with anti-infective drugs until a definite diagnosis can be established. Although, to date, only small case series have been published, the objective of the current study was to investigate a large case series of patients with AM. STUDY DESIGN AND METHODS: The pharmacovigilance safety database of a 10% liquid IG (Gammagard Liquid) was queried for all reports of AM...
December 2016: Transfusion
keyword
keyword
54047
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"